Novo Nordisk has embarked on significant collaborations aimed at enhancing its pipeline for cardiometabolic disorders. The largest involves a multi-year research collaboration with Replicate Bioscience to utilize self-replicating RNA (srRNA) technology, potentially yielding new therapeutic options for obesity and type 2 diabetes, backed by up to $550 million in payments. The alliance builds on Novo's ongoing investments in RNA-based modalities, complementing past acquisitions like Dicerna Pharmaceuticals. This strategic emphasis on RNA tools is designed to accelerate novel drug discovery and ensure competitive positioning in metabolic disease treatment. Additionally, Novo's partnerships with several biotech ventures reinforce a multi-pronged approach to expanding disease-modifying agents for cardio-metabolic conditions.